Quince Therapeutics to acquire EryDel

24 July 2023

California, USA-bas biotech Quince Therapeutics (Nasdaq: QNCX) today announced that it has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments.

Italy-headquartered EryDel has developed an autologous intracellular drug encapsulation (AIDE) technology and a Phase III lead asset, EryDex, targeting a rare fatal pediatric neurological disease, ataxia-telangiectasia (A-T), which currently has no approved treatments and an estimated billion-dollar peak sales opportunity, said Quince, which earlier this year itself rejected an unsolicited takeover bid from Echo Lake Capital.

Quince’s shares were down 18% at $1.29 in early regular trading, having risen as much as 21% to $1.91 in pre-market activity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK